FDA Grants Fast Track Status to Invikafusp Alfa
The drug is now designated for the treatment of TMB-H solid tumors regardless of their tissue origin.
Updated on Oct. 15, 2026 in Cancer
The FDA has expanded its Fast Track designation for the investigational cancer drug invikafusp alfa to include high tumor mutational burden (TMB-H) solid tumors. This status aims to accelerate the development of the drug, which remains unapproved by regulatory authorities.
Why it matters
Fast Track designation is intended to facilitate the review of new therapies for serious conditions with unmet medical needs. By simplifying the development process, the FDA aims to bring potential treatments to patients facing limited options more quickly.
Invikafusp alfa targets TMB-H solid tumors, which are clinically defined as having at least 10 mutations per megabase. The drug remains an investigational bispecific dual T-cell agonist and has not received approval from the FDA or any other authority.
The players
Food and Drug Administration
The agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and medical devices.
European Society for Medical Oncology
This professional organization is a global leader in oncology, providing a platform for information exchange and education for cancer research professionals.
The details
The investigational drug operates by combining an agonist antibody targeting Vbeta6 and Vbeta10 T-cell receptor regions fused to interleukin-2. This mechanism triggers non-clonal T-cell receptor activation and provides a co-stimulatory signal to expand effector memory T cells.
Timeline
June 16, 2020: FDA granted accelerated approval to pembrolizumab for TMB-H tumors.
January 2025: Invikafusp alfa received its first Fast Track designation for colorectal cancer.
October 15, 2026: FDA granted the second Fast Track designation for invikafusp alfa.
October 23, 2026: Updated phase 2 results were presented at the ESMO Congress in Madrid.
The Big Picture
This development follows the precedent set by the 2020 accelerated approval of pembrolizumab for TMB-H tumors. It further reinforces the growing importance of tumor mutational burden as a key predictive biomarker for immunotherapy across diverse cancer types.
This designation may shorten the timeline for the drug to reach clinical availability for patients with TMB-H solid tumors. However, patients should consult their oncologists regarding current treatment standards as the drug is not yet approved.
The takeaway
The expansion of Fast Track status underscores the FDA's ongoing focus on tissue-agnostic therapies. Patients and their families are encouraged to monitor clinical trial databases for potential enrollment opportunities as research progresses.
Further reading
Learn more about evolving treatment paradigms by exploring the Cancer section.
